Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 11/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 9/20 | 0.52 |
| ▸ | MAPT | P10636 | 6/20 | 0.52 |
| ▸ | HTT | P42858 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 5/20 | 0.50 |
| ▸ | TRPM8 | Q7Z2W7 | 5/20 | 0.50 |
| ▸ | PPP1CA | P62136 | 7/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.49 |
| ▸ | MEN1 | O00255 | 5/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | MITF | O75030 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2821103 | 0.86 | L3MBTL1 (0.57) | L3MBTL1SMN1; SMN2MAPTHTTKDM4E | |
| SCHEMBL1443064 | 0.79 | L3MBTL1 (0.65) | L3MBTL1SMN1; SMN2MAPTHTTKDM4E | |
| SCHEMBL913862 | 0.74 | TDO2 (0.50) | L3MBTL1SMN1; SMN2MAPTHTTKDM4E | |
| SCHEMBL10270342 | 0.74 | L3MBTL1 (0.65) | L3MBTL1SMN1; SMN2MAPTHTTKDM4E | |
| SCHEMBL1442223 | 0.71 | LMNA (0.67) | L3MBTL1SMN1; SMN2MAPTHTTKDM4E | |
| SCHEMBL1443054 | 0.69 | TRPM8 (0.60) | L3MBTL1SMN1; SMN2MAPTHTTKDM4E | |
| SCHEMBL23837648 | 0.69 | TRPM8 (0.73) | L3MBTL1SMN1; SMN2MAPTHTTKDM4E | |
| SCHEMBL1443569 | 0.69 | L3MBTL1 (1.00) | L3MBTL1SMN1; SMN2MAPTHTTKDM4E | |
| SCHEMBL3134723 | 0.69 | KDM4E (0.44) | L3MBTL1SMN1; SMN2MAPTHTTKDM4E | |
| SCHEMBL2822092 | 0.68 | KMT2A (0.56) | L3MBTL1SMN1; SMN2MAPTHTTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1742634-B1 | POLYCYCLIC PYRIMIDINES AS POTASSIUM ION CHANNEL MODULATORS | ICAGEN INC (US) | 2010-10-27 | — | — | EP | disclosed |
| US-7560464-B2 | Polycyclic pyrimidines as potassium ion channel modulators | ICAGEN, INC. (US) | 2009-07-14 | — | — | US | disclosed |
| US-20050267089-A1 | Polycyclic pyrimidines as potassium ion channel modulators | ICAGEN, INC. (US) | 2005-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267089-A1 | Polycyclic pyrimidines as potassium ion channel modulators | KCNJ2, KCNJ1, KCNJ11 | L3MBTL1 4011/4885SMN1; SMN2 3689/4885MAPT 3826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.